Late in the summer of 2015, it was one solitary tweet by Hillary Clinton which, in retaliation to Martin Shkreli’s infamous “price gouging”, warned biotech and pharma companies to lower prices for their drugs, that was the catalyst which not only burst the biotech bubble but unleashed a chain of events that culminated with the worst year on record for momentum-gathering investors in alpha clothing such as Bill Ackman. It may have also top-ticked the overall market as it forced the best performing “momo” strategy of recent years to finally fizzle.
– Big Pharma profiteering gone wild: $1,000-a-pill Hepatitis drug in USA sells for less than $10 in Egypt (Natural News, March 26, 2014):
The financial raping of America by Big Pharma has just achieved a new milestone with the impending launch of a Hepatitis C drug that costs $1,000 a pill. If you’ve ever wondered why U.S. health care is so unaffordable and inaccessible — and why health insurance costs are bankrupting businesses and municipalities across the nation — this is exactly why. The same drug that sells for $1,000 a pill in the USA — named “Sovaldi” — sells for just $10 in Egypt, or 1/100th the USA price.
Egypt’s spiralling threat of hepatitis C virus – already the highest incidence rate in the world — is alarming researchers who fear a potential epidemic of the blood-borne disease could spread across the most populous Arab country.
The findings of a recent study published in the National Academy of Sciences showed that more than 500,000 new HCV infection cases occur in Egypt every year. Much of the problem behind the soaring infectious rates is poor healthcare oversight and erratic medical hygiene.
“Nearly seven out of every 1,000 Egyptians acquire HCV infections every year. This is the highest level of HCV transmission ever recorded at a national level for a disease transmitted by use of non-sterile medical instruments,” says Dr. F. DeWolfe Miller, lead author of the study.